New diabetes clinical trial: The Role of Glucagon-Like Peptide-1 Receptor Agonists in Coronary Artery Diseases and Their Potential Mechanisms
Published on: July 17, 2025 at 11:00PM
Conditions: Glucagon-Like Peptide-1 Receptor Agonists; Type 2 Diabetes; Coronary Arterial Disease (CAD)
Interventions: Drug: Semaglutide 1.0 mg; Drug: Semaglutide 0.5 mg
Sponsors: Taipei Veterans General Hospital, Taiwan
Not yet recruiting
https://ift.tt/zabGgIn
Conditions: Glucagon-Like Peptide-1 Receptor Agonists; Type 2 Diabetes; Coronary Arterial Disease (CAD)
Interventions: Drug: Semaglutide 1.0 mg; Drug: Semaglutide 0.5 mg
Sponsors: Taipei Veterans General Hospital, Taiwan
Not yet recruiting
https://ift.tt/zabGgIn
Comments
Post a Comment